drugset / Trial / NCT00884260

GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China

NCT00884260

Phase 3 Completed 918 enrolled Bayer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy, safety, bleeding pattern of low dose LNG (12 mg/ 24 hrs), delivered locally by a new intrauterine contraceptive system suitable for use by women 18 to 40 years of age. In addition, pharmacokinetic assessments will be performed.

Timeline

Start
2009-04
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 12 ug Other

Indications

No indication recorded.